A new round of epidemic struck, and the cumulative number of confirmed cases in the fifth wave in Hong Kong has exceeded 520000. These two days, the epidemic situation in Beijing and Shanghai has suddenly become severe.
However, on the 9th, China Meheco Group Co.Ltd(600056) under the direct management of the state owned assets supervision and Administration Commission of the State Council confirmed to win the sales right of Pfizer covid-19 specific drug in the mainland in 2022.
Previously, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and conditionally approved the import registration of Pfizer covid-19 virus treatment drug paxlovid.
PAXLOVID is an oral small molecule COVID-19 virus therapy for the treatment of mild to moderate New Coronavirus pneumonia (COVID-19) in adults with severe risk factors, such as elderly, chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease.
According to the research results of paxlovid, a new oral antiviral candidate of covid-19 published by Pfizer in 2021, the interim analysis shows that the drug reduces the risk of hospitalization and death of high-risk covid-19 patients by 89%. This data is even better than covid-19 neutralizing antibody, which is significantly better than mosadon molnupiravir.
daily limit for 4 consecutive trading days
“three swordsmen in East Asia” buy together
The news about China Meheco Group Co.Ltd(600056) holding hands with Pfizer has been fermenting for a week. In the afternoon of March 2, due to the rumor that China Meheco Group Co.Ltd(600056) cooperated with covid-19 virus treatment drugs of a multinational pharmaceutical company, the stock price of China Meheco Group Co.Ltd(600056) rose sharply and rose by the limit. On March 3, China Meheco Group Co.Ltd(600056) confirmed the rumor, and the second board rose the limit. On March 4 and March 7, China Meheco Group Co.Ltd(600056) again raised the limit.
On the afternoon of September 9, driven by the recovery of the market, China Meheco Group Co.Ltd(600056) strongly rose by 2.55%, and the share price rose by about 70% in just six trading days.
According to the dragon and tiger list on March 7, “three swordsmen in East Asia” spent 125 million to buy, and Wenzhou Gang (Caixin Shanghai Dalian Road) bought 55.41 million.
shares are boiling
For this major good, some investors believe that it is a major good to cash in and die in sight; Some investors also believe that China Meheco Group Co.Ltd(600056) will copy the trend of Andon Health Co.Ltd(002432) and the share price will take off.
China Meheco Group Co.Ltd(600056) : it is estimated that related businesses account for a relatively small proportion
When Pfizer’s covid-19 drugs enter China, we are most concerned about the price. It is understood that the drug costs $530 (about 3339 yuan) for a course of treatment in the United States.
However, the drug is mainly used for patients with moderate to severe covid-19 pneumonia. In view of the majority of mild and asymptomatic patients in China, China Meheco Group Co.Ltd(600056) also said that even if the cooperation is carried out smoothly, the final use and sales of relevant drugs are affected by factors such as epidemic prevention and control, there is great uncertainty, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, It has no significant impact on the company’s recent operating performance.
Pfizer specific drug related stocks have taken off
Although the sales situation in China may not be as expected, from a global perspective, paxlovid is facing capacity pressure in the short term, and the industrial chain of large-scale process is expected to generate huge benefits.
Pfizer expects paxlovid to produce 6 million courses in the first quarter of 2022, 30 million courses in the first half of 2022 and 120 million courses in the whole year. With the continuation of the global covid-19 epidemic, the pressure on production capacity will further increase. This also brings opportunities to relevant cdmo enterprises in China.
In fact, since November 2021, the news that Pfizer has reached huge orders with many cdmo enterprises in China has spread widely.
On November 16, 2021, Asymchem Laboratories (Tianjin) Co.Ltd(002821) announced that the wholly-owned subsidiary will provide contract customized R & D and production (cdmo) services for a small molecule chemical innovative drug of a large pharmaceutical company in the United States. The cumulative contract amount of cdmo services for this product is about RMB 3.1 billion ( Asymchem Laboratories (Tianjin) Co.Ltd(002821) 2020 total revenue is RMB 3.15 billion, and this order is almost equal to its one-year revenue in 2020). On November 28, 2021, Asymchem Laboratories (Tianjin) Co.Ltd(002821) said that it continued to provide contract customized R & D and production (cdmo) services for a small molecule chemical innovative drug of a pharmaceutical company, and the amount of new orders was equivalent to about 2.72 billion yuan. On February 20, 2022, Asymchem Laboratories (Tianjin) Co.Ltd(002821) again announced that it continued to provide contract customized R & D and production (cdmo) services for a small molecule chemical innovative drug of a pharmaceutical company, with a new order amount equivalent to about 3.542 billion yuan.
Based on these three cdmo orders, Asymchem Laboratories (Tianjin) Co.Ltd(002821) accumulated revenue of more than 9 billion yuan, which is equivalent to three times of Asymchem Laboratories (Tianjin) Co.Ltd(002821) 2020 revenue of 3.15 billion yuan and twice of the expected 2021 revenue of 4.505 billion yuan. Dongguan Securities Research Report believes that Asymchem Laboratories (Tianjin) Co.Ltd(002821) continues to sign large orders, which provides a guarantee for the high growth of performance in 2022.
During this period, the share price of Asymchem Laboratories (Tianjin) Co.Ltd(002821) once rose from less than 400 yuan to around 530 yuan.
In addition to Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Porton Pharma Solutions Ltd(300363) has also become a major beneficiary. On February 11, Porton Pharma Solutions Ltd(300363) before the announcement of Pfizer covid-19 oral drug approval in China, announced that the company had received a new batch of purchase orders from Pfizer, and the company would provide contract customized R & D and production (cdmo) services. As of the disclosure date of the announcement, the total amount of new orders obtained by boten was US $681 million, more than 50% of the audited operating revenue of the company in the latest fiscal year. The delivery time of this order is 2022. Affected by this good news, the daily limit of Porton Pharma Solutions Ltd(300363) opened on the same day.
On the 9th, it was rumored that Zhejiang Jianfeng Group Co.Ltd(600668) , like Porton Pharma Solutions Ltd(300363) , would undertake Pfizer’s customized R & D and production (cdmo) orders, repeatedly hit the board, and finally rose by 8.16%.
It is understood that Zhejiang Jianfeng Group Co.Ltd(600668) Shanghai North Carolina Pharmaceutical Co., Ltd. produces uridine and carbonic anhydride (carbonic anhydride), which are the raw materials required for the two covid-19 oral drugs of MSD and Pfizer respectively. However, up to now, Zhejiang Jianfeng Group Co.Ltd(600668) said that it had not signed any cooperation agreement with Pfizer and had not supplied any products to Pfizer.
In addition, Chengda pharmaceutical has nearly doubled its share price since the bottom because it took the ride of covid-19 oral medicine.
Recently, relevant research institutions also said that Pfizer authorized the imitation of covid-19 oral drug paxlovid through MPP (Geneva drug patent pool organization), and the list of enterprises is expected to accelerate the implementation. Pfizer has previously authorized 95 countries to produce paxlovid generic drugs through the MPP organization. Considering that the population of 95 MPP member countries has exceeded half of the global total population and the market demand is huge, its final authorization list is expected to be announced in the near future.
Minsheng securities also believes that in January, MPP authorized 27 enterprises to imitate the production of molnupiravir, an oral drug of mosadon covid-19, and the authorized enterprises can sell molnupiravir’s generic drugs in 105 low – and middle-income countries (excluding China). Driven by the imitation production of Pfizer covid-19 oral medicine authorized by MPP, the upstream API and intermediate industry chain is about to usher in huge demand and profit elasticity.
